These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19341185)

  • 1. The putative role of leukotrienes in experimental atherogenesis.
    Jawień J
    Pol Arch Med Wewn; 2009; 119(1-2):90-3. PubMed ID: 19341185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice.
    Jawien J; Gajda M; Rudling M; Mateuszuk L; Olszanecki R; Guzik TJ; Cichocki T; Chlopicki S; Korbut R
    Eur J Clin Invest; 2006 Mar; 36(3):141-6. PubMed ID: 16506957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current view on the role of leukotrienes in atherogenesis.
    Jawien J; Korbut R
    J Physiol Pharmacol; 2010 Dec; 61(6):647-50. PubMed ID: 21224494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
    Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice.
    Cao RY; St Amand T; Gräbner R; Habenicht AJ; Funk CD
    Atherosclerosis; 2009 Apr; 203(2):395-400. PubMed ID: 18804760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukotrienes and atherosclerosis.
    Riccioni G; Bäck M; Capra V
    Curr Drug Targets; 2010 Jul; 11(7):882-7. PubMed ID: 20388065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy.
    Roos J; Peters M; Maucher IV; Kühn B; Fettel J; Hellmuth N; Brat C; Sommer B; Urbschat A; Piesche M; Vogel A; Proschak E; Blöcher R; Buscató E; Häfner AK; Matrone C; Werz O; Heidler J; Wittig I; Angioni C; Geisslinger G; Parnham MJ; Zacharowski K; Steinhilber D; Maier TJ
    Antioxid Redox Signal; 2018 May; 28(14):1265-1285. PubMed ID: 28699354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice.
    Jawien J; Gajda M; Wołkow P; Zurańska J; Olszanecki R; Korbut R
    J Physiol Pharmacol; 2008 Sep; 59(3):633-9. PubMed ID: 18953103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation.
    Bäck M; Sultan A; Ovchinnikova O; Hansson GK
    Circ Res; 2007 Apr; 100(7):946-9. PubMed ID: 17379835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of antileukotriene drugs in atherosclerosis.
    Spanbroek R; Habenicht AJ
    Drug News Perspect; 2003 Oct; 16(8):485-9. PubMed ID: 14668944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis.
    Peres CM; de Paula L; Medeiros AI; Sorgi CA; Soares EG; Carlos D; Peters-Golden M; Silva CL; Faccioli LH
    Microbes Infect; 2007 Apr; 9(4):483-9. PubMed ID: 17347013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice.
    Jawień J; Gajda M; Olszanecki R; Korbut R
    J Physiol Pharmacol; 2007 Sep; 58(3):583-8. PubMed ID: 17928652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis.
    Stanke-Labesque F; Pépin JL; Gautier-Veyret E; Lévy P; Bäck M
    Cardiovasc Res; 2014 Feb; 101(2):187-93. PubMed ID: 24204032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The significance of leukotrienes in pathophysiology of bronchial asthma--therapy perspectives].
    Wojnowski P; Patkowski J
    Postepy Hig Med Dosw; 1997; 51(5):499-514. PubMed ID: 9489451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukotriene signaling in atherosclerosis and ischemia.
    Bäck M
    Cardiovasc Drugs Ther; 2009 Feb; 23(1):41-8. PubMed ID: 18949546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukotriene inhibitors and antagonists in asthma.
    Spector SL
    Ann Allergy Asthma Immunol; 1995 Dec; 75(6 Pt 1):463-70, 473; quiz 473-4. PubMed ID: 8603274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No effect of C-reactive protein on early atherosclerosis in LDLR-/- / human C-reactive protein transgenic mice.
    Torzewski M; Reifenberg K; Cheng F; Wiese E; Küpper I; Crain J; Lackner KJ; Bhakdi S
    Thromb Haemost; 2008 Jan; 99(1):196-201. PubMed ID: 18217154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modulation of leukotriene pathway - potential targets].
    Peter H; Lýdia B
    Ceska Slov Farm; 2012 Jun; 61(3):101-6. PubMed ID: 22913825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukotrienes in atherosclerosis: new target insights and future therapy perspectives.
    Riccioni G; Zanasi A; Vitulano N; Mancini B; D'Orazio N
    Mediators Inflamm; 2009; 2009():737282. PubMed ID: 20150962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukotrienes in respiratory disease.
    McMillan RM
    Paediatr Respir Rev; 2001 Sep; 2(3):238-44. PubMed ID: 12052325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.